TY - JOUR T1 - Cutaneous Granulomas During Infliximab Therapy for Spondyloarthropathy JF - The Journal of Rheumatology JO - J Rheumatol SP - 1222 LP - 1224 VL - 35 IS - 6 AU - ANDRA ECONOMU DUBOSC AU - ANNE-MARIE PERROUD AU - VALÉRIE FARENQ AU - BERNARD MAITRE AU - PASCAL CLAUDE-PIERRE AU - MARTINE BAGOT AU - XAVIER CHEVALIER Y1 - 2008/06/01 UR - http://www.jrheum.org/content/35/6/1222.abstract N2 - To the Editor: Tumor necrosis factor-α (TNF-α) antagonists are highly effective drugs that have radically improved the functional outcomes and quality of life of many patients with inflammatory diseases. Although TNF-α antagonists are generally well tolerated and safe, the list of reported adverse events is growing steadily. The most common adverse events are infectious diseases including potentially severe infections due to intracellular organisms; allergic reactions including urticaria, rash, and stomatitis1; and biological autoimmune disorders. In addition, dermatological events not reported in premarketing clinical trials but seen in everyday rheumatologic and dermatology practice2 include acne3, eczema4,5, psoriasis6–8, vasculitis9, bullous lesions10,… ER -